Clinical Trials
19
Active:2
Completed:5
Trial Phases
3 Phases
Phase 1:1
Phase 4:3
Not Applicable:10
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Not Applicable
10 (71.4%)Phase 4
3 (21.4%)Phase 1
1 (7.1%)Comparative Efficacy of 3L and 2L Integrated Techniques for Gynecologic Cancer-related Lower Extremity Lymphedema: a Retrospective Study
Completed
- Conditions
- LymphedemaGynecologic Cancer-related Lower Extremity Lymphedema
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Zunyi Medical College
- Target Recruit Count
- 125
- Registration Number
- NCT06920732
- Locations
- 🇨🇳
Department of Burns and Plastic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
The Trajectory and Influencing Factors of Cognitive Level in ICU Delirium Patients After Transfer Out of the ICU
- Conditions
- Cognition DisorderICUDelirium
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Zunyi Medical College
- Target Recruit Count
- 240
- Registration Number
- NCT06674603
- Locations
- 🇨🇳
Affiliated Hospital of Guizhou Vocational Nursing Technology College, Guiyang, Guizhou, China
Mindfulness Training Improves Emotions Among Female Abdominal Cancer Patients
Not Applicable
Completed
- Conditions
- Mindfulness Training
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Zunyi Medical College
- Target Recruit Count
- 60
- Registration Number
- NCT06473636
- Locations
- 🇨🇳
Zunyi Medical University, Zunyi, Guizhou, China
A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy
Phase 1
Recruiting
- Conditions
- HER-2 Positive Advanced Breast Cancer
- Interventions
- Drug: A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy
- First Posted Date
- 2024-06-24
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Zunyi Medical College
- Target Recruit Count
- 67
- Registration Number
- NCT06470347
- Locations
- 🇨🇳
Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
CYP2C19 Genotype-Guided P2Y12 Receptor Inhibitor Selection After Complex Percutaneous Coronary Intervention
Phase 4
Recruiting
- Conditions
- ACS - Acute Coronary SyndromeCYP2C19 Polymorphism
- Interventions
- Drug: CYP2C19 Genotype Guided DAPT
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Zunyi Medical College
- Target Recruit Count
- 1200
- Registration Number
- NCT06283888
- Locations
- 🇨🇳
Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found